XML 27 R11.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Intangibles, net | 12 Months Ended
--- | ---
Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract] |
Intangibles, net | Intangibles, net As of December 31, 2018, the Company's identifiable intangible assets consisted of acquired ARIKAYCE R&D, formerly referred to as in-process research and development, and a milestone paid to PARI Pharma GmbH (PARI) for the license to use PARI's Lamira® Nebulizer System for the delivery of ARIKAYCE to patients. The Company's only identifiable intangible asset was in-process research and development (IPRD) related to ARIKAYCE as of December 31, 2017, which resulted from the initial amount recorded at the time of the Company's merger with Transave in 2010 and subsequent adjustments in the value. On September 28, 2018, as a result of the FDA approval of ARIKAYCE, the Company recorded a milestone payment of $1.7 million due to PARI. Total intangible assets, net was $58.7 million and $58.2 million as of December 31, 2018 and 2017, respectively. Intangible assets are measured at their respective fair values on the date they were recorded and, with respect to the Acquired ARIKAYCE milestone, at the date of subsequent adjustments of fair value. The Company began amortizing its intangible assets October 1, 2018, over ARIKAYCE's initial regulatory exclusivity period of 12 years. Amortization of intangible assets during each of the next five years is estimated to be approximately $5.0 million per year. The Company performed its annual impairment test as of October 1, 2018. The Company performed a qualitative assessment to evaluate whether there was an impairment of the assets. This assessment did not identify any indicators of impairment of the intangible assets as of that date. A rollforward of the Company's intangible assets for the years ended December 31, 2018 and 2017 follows:
| 2018
Intangible Asset | January 1, | Additions | Amortization | December 31,
Acquired ARIKAYCE R&D | $ | 58,200 |  | $ | — |  | $ | (1,212 | ) | $ | 56,988 |
PARI milestone upon FDA approval | — |  | 1,724 |  | (37 | ) | 1,687 |
| $ | 58,200 |  | $ | 1,724 |  | $ | (1,249 | ) | $ | 58,675 |
| 2017
Intangible Asset | January 1, | Additions | Amortization | December 31,
Acquired ARIKAYCE IPRD | $ | 58,200 |  | $ | — |  | $ | — |  | $ | 58,200 |
| $ | 58,200 |  | $ | — |  | $ | — |  | $ | 58,200 |

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for all or part of the information related to intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_IntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration